forecast
Biotech VC May Work Despite Difficulty
Although biotech is more regulated and historically less profitable for venture capital, the past isn't a guide to the future: innovations like gene sequencing and CRISPR make drug development faster and cheaper, and successes like Genentech's 1980 IPO and Moderna's COVID vaccine suggest even capital- and regulation-intensive biotech can work for VC.
forecastpending
Speaker
Sebastian MallabyEvidence Quote
“I think that it would be wrong to rule out the idea that even a pretty capital-intensive, regulation-intensive sector like biotech — I think it might still work.”
Created: 6/13/2026, 3:25:18 AM
Your notes
Loading notes...